HomeAI · summaries
Storia in 2 fonti
Teva Reports Early Skin Repigmentation Data, Preps For Next Trial - Teva Pharmaceutical Indus (NYSE:TEVA)
Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
ynetnews.com
Teva advances experimental vitiligo drug after encouraging early results
Israeli drugmaker says TEV-408, an anti-IL-15 antibody designed for quarterly dosing, improved skin pigmentation in an early-stage study and will move into Phase 2b development…
- ·
benzinga.com
Teva Reports Early Skin Repigmentation Data, Preps For Next Trial - Teva Pharmaceutical Indus (NYSE:TEVA)
Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.
- ·
Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study - Forte Bi
Forte Biosciences reported positive Phase 1b vitiligo data, with FB102 showing significant facial repigmentation and favorable safety.